A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor

被引:72
作者
Abhyankar, S. [1 ]
DeJarnette, S. [2 ]
Aljitawi, O. [1 ]
Ganguly, S. [1 ]
Merkel, D. [2 ]
McGuirk, J. [1 ]
机构
[1] Univ Kansas, Med Ctr, Blood & Marrow Transplant Program, Westwood, KS 66205 USA
[2] Univ Kansas, Hosp Med, Blood & Marrow Transplant Program, Westwood, KS 66205 USA
关键词
stem; plerixafor; autologous; cell; mobilization; transplant; MULTIPLE-MYELOMA; PROGENITOR CELLS; G-CSF; MOBILIZATION; BLOOD; AMD3100; TRANSPLANTATION; CHEMOTHERAPY; COUNTS;
D O I
10.1038/bmt.2011.133
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Autologous hematopoietic stem cell (HSC) transplant is an effective treatment for patients with hematological malignancies. Unfortunately, 15-30% of patients fail to mobilize a sufficient number of HSCs for the transplant. Plerixafor is now used as a salvage mobilization regimen, with good success. We describe here a risk-based approach for the use of plerixafor, based on the circulating CD34(+) cell count and the CD34(+) cell dose collected after 4 days of G-CSF, that identifies potential poor HSC mobilizers upfront. A total of 159 patients underwent HSC collections using this approach. Of these, 55 (35%) were identified as high risk owing to low CD34(+) cell number or low yield on day 1 of collection, and received plerixafor on the subsequent days of collection. Of the 159 patients, 151 (95%) were able to provide adequate collections with the first mobilization attempt in a median of 1.7 days using this approach. Of the eight who failed initial mobilization, 5 successfully underwent re-mobilization with plerixafor and G-CSF and 3 (1.9%) were mobilization failures. This approach helped to control the overall cost of HSC collections for our BMT program by decreasing the need for remobilization, reducing the number of collection days and avoiding the use of plerixafor in all patients. Bone Marrow Transplantation (2012) 47, 483-487; doi:10.1038/bmt.2011.133; published online 4 July 2011
引用
收藏
页码:483 / 487
页数:5
相关论文
共 19 条
[1]   Hematopoietic stem cell transplantation for multiple myeloma beyond 2010 [J].
Blade, Joan ;
Rosinol, Laura ;
Cibeira, Maria Teresa ;
Rovira, Montserrat ;
Carreras, Enric .
BLOOD, 2010, 115 (18) :3655-3663
[2]   Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist [J].
Broxmeyer, HE ;
Orschell, CM ;
Clapp, DW ;
Hangoc, G ;
Cooper, S ;
Plett, PA ;
Liles, WC ;
Li, XX ;
Graham-Evans, B ;
Campbell, TB ;
Calandra, G ;
Bridger, G ;
Dale, DC ;
Srour, EF .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (08) :1307-1318
[3]   CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers [J].
Burger, J. A. ;
Peled, A. .
LEUKEMIA, 2009, 23 (01) :43-52
[4]   AMD3100 plus G-CSF can successfully mobilize CD34+cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data [J].
Calandra, G. ;
McCarty, J. ;
McGuirk, J. ;
Tricot, G. ;
Crocker, S-A ;
Badel, K. ;
Grove, B. ;
Dye, A. ;
Bridger, G. .
BONE MARROW TRANSPLANTATION, 2008, 41 (04) :331-338
[5]   Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization [J].
Costa, L. J. ;
Alexander, E. T. ;
Hogan, K. R. ;
Schaub, C. ;
Fouts, T. V. ;
Stuart, R. K. .
BONE MARROW TRANSPLANTATION, 2011, 46 (01) :64-69
[6]   Monitoring of peripheral blood CD34+cell counts on the first day of apheresis is highly predictive for efficient CD34+cell yield [J].
Demirer, T ;
Ilhan, O ;
Ayli, M ;
Arat, M ;
Dagli, M ;
Ozcan, M ;
Haznedar, R ;
Genc, Y ;
Fen, T ;
Ayyildiz, E ;
Dincer, S ;
Arslan, O ;
Gurman, G ;
Konuk, N ;
Dalva, K ;
Uysal, A ;
Koc, H ;
Ozet, G ;
Akan, H .
THERAPEUTIC APHERESIS, 2002, 6 (05) :384-389
[7]   Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma [J].
DiPersio, John F. ;
Micallef, Ivana N. ;
Stiff, Patrick J. ;
Bolwell, Brian J. ;
Maziarz, Richard T. ;
Jacobsen, Eric ;
Nademanee, Auayporn ;
McCarty, John ;
Bridger, Gary ;
Calandra, Gary .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4767-4773
[8]   Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma [J].
DiPersio, John F. ;
Stadtmauer, Edward A. ;
Nademanee, Auayporn ;
Micallef, Ivana N. M. ;
Stiff, Patrick J. ;
Kaufman, Jonathan L. ;
Maziarz, Richard T. ;
Hosing, Chitra ;
Frueehauf, Stefan ;
Horwitz, Mitchell ;
Cooper, Dennis ;
Bridger, Gary ;
Calandra, Gary .
BLOOD, 2009, 113 (23) :5720-5726
[9]   AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties [J].
Kalatskaya, Irina ;
Berchiche, Yamina A. ;
Gravel, Stephanie ;
Limberg, Brian J. ;
Rosenbaum, Jan S. ;
Heveker, Nikolaus .
MOLECULAR PHARMACOLOGY, 2009, 75 (05) :1240-1247
[10]   Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells [J].
Lapidot, T ;
Petit, I .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (09) :973-981